

Review

Recent Developments in *Inonotus obliquus* (Chaga mushroom) Polysaccharides: Isolation, Structural Characteristics, Biological Activities and Application

Yangpeng Lu, Yanan Jia, Zihan Xue, Nannan Li, Junyu Liu and Haixia Chen * 

Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China; roylu@tju.edu.cn (Y.L.); jyn1021@126.com (Y.J.); xzh078@tju.edu.cn (Z.X.); 13234039725@163.com (N.L.); junyuliu@tju.edu.cn (J.L.)

* Correspondence: chenhx@tju.edu.cn; Tel.: +86-22-2740-1483

Abstract: *Inonotus obliquus* (Chaga mushroom) is a kind of medicine and health food widely used by folk in China, Russia, Korea, and some occidental countries. Among the extracts from *Inonotus obliquus*, *Inonotus obliquus* polysaccharide (IOPS) is supposed to be one of the major bioactive components in *Inonotus obliquus*, which possesses antitumor, antioxidant, anti-virus, hypoglycemic, and hypolipidemic activities. In this review, the current advancements on extraction, purification, structural characteristics, and biological activities of IOPS were summarized. This review can provide significant insight into the IOPS bioactivities as their in vitro and in vivo data were summarized, and some possible mechanisms were listed. Furthermore, applications of IOPS were reviewed and discussed; IOPS might be a potential candidate for the treatment of cancers and type 2 diabetes. Besides, new perspectives for the future work of IOPS were also proposed.

Keywords: *Inonotus obliquus*; polysaccharides; hypoglycemic; anti-tumor; antiviral; applications



Citation: Lu, Y.; Jia, Y.; Xue, Z.; Li, N.; Liu, J.; Chen, H. Recent Developments in *Inonotus obliquus* (Chaga mushroom) Polysaccharides: Isolation, Structural Characteristics, Biological Activities and Application. *Polymers* **2021**, *13*, 1441. <https://doi.org/10.3390/polym13091441>

Academic Editors: Ângela Maria Almeida de Sousa and Barbara Klajnert-Maculewicz

Received: 19 March 2021
Accepted: 27 April 2021
Published: 29 April 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

According to World Health Statistics 2020, global life expectancy increased from 66.5 years to 72.0 years during 2000 to 2016 [1]. Although the total risk of dying from any of diseases at the age of 30–70 decreased by 18%, the rate of premature deaths (defined as deaths between 30 and 70 years old) caused by diabetes has increased by 5% during this period. Recent statistics from Center for Disease Control and Prevention (CDC) has shown that 34.2 million people within the United States have diabetes till the end of 2020, which took up 10.5% of the whole population [2]. In high-income countries such as the US and EU countries, cancer has become the leading cause of premature death [1]. The American Cancer Society estimated that 1.9 million new cancer cases will be diagnosed and the number of nation-wide cancer deaths will rise to 608,570 in 2021 [3]. Beside reasonable prevention, it is also necessary and urgent to find suitable drugs to cure the disease. Unfortunately, existing chemical and biological drugs for cancers and diabetes have many drawbacks, such as large side effects and high prices [4–6]. Therefore, natural products that possess hypoglycemic, anti-oxidation, and anticancer properties is of great significance and drew the researchers' attention [6–9].

As early as the 16th century, *Inonotus obliquus* was used as a folk medicine in Russia, Siberia, and some occidental countries [10,11]. It is a kind of fungus that mostly parasitize on living trunk of birch trees in the cold circumboreal region of the northern hemisphere areas [12,13]; it is also named Chaga mushroom due to its irregularly formed sterile conk with burnt charcoal like appearance [13]. Owing to abundant melanin, the sclerotium and mycelium are mostly black [14]. As most of them grow in high latitudes, the extremely low environmental temperature makes the fungus grow very slow. Thus, in the last two decades, its main active components and pharmacological research have received

growing attention. As shown in Table 1, owing to various chemical components including polysaccharides, triterpenoids, polyphenols, and melanin, it has been proven to possess anticancer, anti-inflammatory, antiviral, antioxidant, hypoglycemic, and hypolipidemic activity without obvious side-effects by long-term clinical and animal experiments [15–17].

Table 1. Biological activities of *Inonotus obliquus* main components.

| Component | Biological Activities | References |
|----------------|--|------------|
| Polysaccharide | Anticancer, anti-inflammatory, antiviral, antioxidant, immunomodulatory, hypoglycemic, hypolipidemic, hepatoprotective, etc. | [18–24] |
| Polyphenol | Antioxidant | [25] |
| Triterpenoid | Anticancer, anti-inflammatory, antiviral, and antioxidant | [26–30] |
| Melanin | Antioxidant, anti-inflammatory, antiviral, hypolipidemic and immunomodulatory | [24,31–34] |

Polysaccharides are natural biopolymers that all living organisms have. And the diversity in monosaccharide composition and structure causes them to have different biological activities [35]. Modern research has shown that polysaccharides are involved in various bioactivities such as cell recognition, cell growth, differentiation, metabolism, embryonic development, cell cancerization, virus infection, immune response [36], etc., which are crucial for life maintenance [35]. Relevantly, it is a hot area of modern medicine and food functional chemistry research. Over several decades, remarkable progress has been realized, and especially during the past decade, polysaccharides' anticancer, hypoglycemic, and antiviral effects were popular research topics.

Among all the active components in *Inonotus obliquus*, *Inonotus obliquus* polysaccharides have the broadest biological activity, such as anticancer, hypoglycemic, anti-inflammatory, and anti-oxidation effects [8,22,37–61]. Through the number of Scopus-indexed publication numbers (archived until 15 March 2021) for polysaccharide bioactivity, *Inonotus obliquus*, *Inonotus obliquus* polysaccharide related articles, a certain degree of upward trend can be seen (Figure 1), which means that the medicinal value and health value of *Inonotus obliquus* have been widely recognized and affirmed [5,6,62–64], making it worthwhile to review *Inonotus obliquus* polysaccharides.




Figure 1. Scopus-indexed publication numbers for polysaccharide bioactivity, *Inonotus obliquus*, *Inonotus obliquus* polysaccharide related articles. (Archived until 15 March 2021).

In this review, the extraction, purification methods, and the physiochemical and structural features of *Inonotus obliquus* polysaccharides are summarized and discussed in detail; besides, the in vitro and in vivo evaluation and mechanisms of its bioactivities are summarized. Furthermore, the application and future perspectives are presented.

2. Extraction and Purification Methods

2.1. Extraction of IOPS

As shown in Table 2, Chen Yiyong analyzed the composition of *Inonotus obliquus* raw material; the percentage of each components are (the data were presented as means \pm SD, %): moisture 3.5 ± 0.36 , crude protein 2.4 ± 0.44 , crude fat 1.7 ± 0.25 , ash 10.4 ± 0.44 , crude fiber 67.5 ± 0.95 , reducing sugar 4.2 ± 0.30 , polysaccharide 10.3 ± 0.40 , respectively [15]. As most polysaccharides have good water solubility, the classic method uses hot water reflux to extract polysaccharides, Gao determined the optimal process for traditional water extraction by orthogonal experiments, 80 °C for temperature, 1.5 h for time, 1:40 (*w/v*) for material-to-liquid ratio, the yield for IOPS is 2.53% [65]. Despite that this method is simple and easy to implement, the efficiency was very low, the yield of IOPS varies from 2.12% to 2.53% [15,66].

Table 2. Composition of *Inonotus obliquus* raw material.

| Composition | Percentage Content (Mean \pm SD, %) |
|----------------|---------------------------------------|
| Moisture | 3.5 ± 0.36 |
| Crude protein | 2.4 ± 0.44 |
| Crude fat | 1.7 ± 0.25 |
| Ash | 10.4 ± 0.44 |
| Crude fiber | 67.5 ± 0.95 |
| Reducing sugar | 4.2 ± 0.30 |
| Polysaccharide | 10.3 ± 0.40 |

Many people have developed modern physical methods such as microwave assist, ultrasonic heating and air technology, and cellulase-assisted extraction process to improve extraction efficiency [16,58,61,67–71]. Owing to the cavitation effect of ultrasonic heating, it is easier for the solvent to penetrate the cells and accelerate the dissolution of the material than in the usual condition, thus, enhancing the extraction efficacy [72]. Compared with the traditional reflux extraction, the ultrasonic assisted extraction method can not only shorten the extraction time, but also prevent the degradation of the components caused by high temperature, which is an extremely effective extraction method.

Chen used response surface analysis method to determine the optimal process parameters of ultrasonic-microwave-assisted extraction (UMAE), microwave power of 90 W, material-to-liquid ratio of 1:20 (*w/v*), extraction time of 19 min. Compared with the traditional water extraction method, the ultrasonic-microwave-assisted extraction time was significantly shortened while the yield of polysaccharides increased from 2.12% to 3.25% and the purity increased from 64.03% to 73.16% [15]. Dr. Xu further improved and optimized this extraction method; the optimal extraction conditions for IOPS are: ultrasonic treatment for 31 min at 52 °C temperature, with liquid-to-material ratio of 21:1 (mL/g), the IOPS extraction rate grew to $3.81 \pm 0.19\%$ [20].

Zong used the response surface analysis with four factors and three levels to obtain the optimal extraction process for IOPS: extraction by 30% concentration ethanol at 95 °C for 2.5 h, with 30:1 of liquid-to-material ratio. Under this condition, the actual extraction content of IOPS was 5.993%, and the crude polysaccharide yield was 33.6% [73].

Ji used response surface optimization experiments to obtain $16.86 \pm 0.48\%$ yield for water-soluble crude polysaccharide and $28.64 \pm 5.19\%$ for alkali-soluble crude polysaccharides. The extraction temperature was 85 °C and the extraction time was 4.77 h at 43:1 ratio

of liquid to material, and 26 h, with 0.6 mol/L NaOH solution while the liquid-to-material ratio was 28:1 for them [74].

An orthogonal experiment was used by Wang to determine the best process for the ultrasonic method [56]. He found the optimal conditions were an ultrasonic treatment time of 25 min, material-to-liquid ratio of 1:40, ultrasonic temperature of 50 °C, and extraction three times to obtain 8.61% yield; a greatly improved extraction efficiency, comparing to a classical water extraction method. In addition, high-voltage pulsed electric fields and flash extraction methods have also been applied to the extraction of IOPS. The condition and yield of IOPS for different extraction methods are concluded in Table 3.

Table 3. Condition and yield of IOPS for different extraction method.

| Extraction Method | Extracting Temperature (°C) | Extracting Time | Solid/Water Ratio (w/v) | Polysaccharide Yield (%) | References |
|------------------------|-----------------------------|-----------------|-------------------------|--|------------|
| Water Extraction | 80 | 1.5 h | 1:40 | 2.53 | [65] |
| Water Extraction | 85 | 4.77 h | 1:43 | 16.86 ± 0.48 | [74] |
| UMAE | | 19 min | 1:20 | 3.25 | [15] |
| UMAE | 52 | 31 min | | 3.81 ± 0.19 | [20] |
| 30% Ethanol Extraction | 95 | 2.5 h | 1:30 | 5993 | [73] |
| 0.6 mol/L NaOH | | 26 h | 1:28 | 28.64 ± 5.19 (alkali-soluble crude polysaccharides) | [74] |
| Ultrasonic Method | 50 | 25 min | 1:40 | | [56] |

2.2. Purification Method of IOPS

The extracted IOPS contains impurities such as proteins, pigments, and inorganic ions in different contents, so further separation and purification are required. Currently, the traditional Sevag method and the trichloroacetic acid method are used to remove proteins [15,17,66]. Han Yaoling compared the effects of these two methods, and each has its advantages and disadvantages [75]. However, the traditional method relies on chemical reagents that usually lead to pollution. Chen used DEAE-cellulose, Sepharose CL-6B, and Sephadex G-200 column chromatography instead of the traditional method [17]. Liu developed a novel three-phase partitioning (TPP) purification technique with high efficiency and safety, and it was environmentally friendly [66]. Li compared trichloroacetic acid-n-butanol (TCA-NBA) method, hydrochloric acid method, enzymatic method, and other methods [76], among these methods, the enzymatic assisted of trichloroacetic acid-n-butanol deproteinization method presented the best results. The protein removal rate reached 82.3%, and the polysaccharide retention rate was as high as 76.1%, purity of the deproteinized polysaccharide increased to 81.1%. The activated carbon powder, hydrogen peroxide, chitosan, and polyamide chromatography column are used to decolorize the *Inonotus obliquus* polysaccharide, and a polyamide chromatography column with excellent decolorization effect was selected as the appropriate decolorization method. The decolorization rate reached 89.3% and the polysaccharide retention rate was 91.7%. The purity of the decolorized polysaccharide was improved to 85.8%.

3. Physiochemical and Structural Features

The structure of polysaccharides includes primary structure and advanced structure. The primary structure includes monosaccharide composition, connection sequence and the type of glycosidic bond. The high-level structures are divided into secondary, tertiary and quaternary structures. The secondary structure refers to the regular conformation formed by the hydrogen bond; the tertiary structure and the quaternary structure refer to the regular spatial conformation resulting from the non-covalent interaction between saccharide units based on secondary structure [35,77,78].

3.1. Monosaccharide Composition and Glycosidic Bond Connection

The structural units of polysaccharides are monosaccharides, and they are connected by glycosidic bonds. Common glycosidic bonds are α -1,4-, α -1,6-, β -1,3-, and β -1,4-glycosidic bonds. Glycosidic bonds are closely related to polysaccharide activity. The active polysaccharides obtained from bacteria are generally composed of glucose, and the β -(1, 3) -D glycosidic bond on the glucose backbone is necessary for their antitumor effects [3–5].

For the analysis of the primary structure of IOPS monosaccharide composition and glycoside bond connection mode, there are mainly gas chromatography (GC), periodic acid oxidation method, Smith degradation method, and methylation analysis [79].

According to Chen, the composition of IOPS were rhamnose (Rha), arabinose (Ara), xylose (Xyl), mannose (Man), glucose (Glc), galactose (Gal), with molar ratio 10.25:9.38:1:12.45:9.9:11.55. The relative molecular mass of IOPS was 156,611 Da by HPLC gel chromatography column [15]. Xue obtained two polysaccharides IOEP1 and IOEP2 from *Inonotus obliquus* liquid fermentation, IOEP1 mainly composed of galactose and mannose with 20 KDa molecular weight, while IOEP2 mainly composed of arabinose and molecular weight was 200 KDa. He found that IOEP1 and IOEP2 were all pyran-type polysaccharides, glycosidic bonds of IOEP1 and IOEP2 were both α -type and β -type via Fourier-transform infrared (FT-IR) and $^1\text{H-NMR}$ spectra analysis [39].

Li et al. also studied the monosaccharide composition of IOPS by High performance liquid chromatographic (HPLC) method, he used precolumn-derivatization with 1-phenyl-3-methyl-5-pyrazolone (PMP) for the detection. The result showed that IOPS was composed of mannose, rhamnose, glucose, galactose, xylose, and arabinose with molar ratio 2.13:1.36:7.01:2.98:1:1.78 [76].

Chen used DEAE-Sepharose CL-6B column for further separation and purification to obtain four polysaccharides: IOPS1, IOPS2, IOPS3, and IOPS4 [15]. The relative molecular mass of IOPS1 was 153,172 Da and its monosaccharide composition was determined to be glucose by gas chromatography, which was presumed to be a β -glucose. The relative molecular mass of IOPS3 was determined by HPLC to be 44265 Da and its structure was analyzed by methylation analysis method, combined with GC, MS, NMR, and FT-IR methods. Wold et al. found that the glycoside bond connection were mainly: (1 \rightarrow 3)- β -Glc-(1 \rightarrow 3), (1 \rightarrow 6)- β -Glc-(1 \rightarrow 3), (1 \rightarrow 6)- β -Glc-(1 \rightarrow 6), (1 \rightarrow 3)- β -Glc-(1 \rightarrow 6), T- β -Glc-(1 \rightarrow 6), (1 \rightarrow 4)- β -Xyl, T- β -Xyl-(1 \rightarrow 4), (1 \rightarrow 6)- α -Gal-(1 \rightarrow 6), (1 \rightarrow 6)- α -3-O-Me-Gal-(1 \rightarrow 6), (1 \rightarrow 4)- α -GalA-(1 \rightarrow 4), (1 \rightarrow 3)- α -Man, (1 \rightarrow 4)- α -GlcA and (1 \rightarrow 2)- α -Rha [36].

3.2. High-Level Structure of Polysaccharides

There is certain correlation between spatial conformation of polysaccharides and their activities. Large number of studies have shown that polysaccharides in flexed spiral conformation have higher activity than stretchable or wrinkled ribbon-shaped polysaccharides [80,81]. Congo red experiment and UV spectroscopy showed that IOPS3 was a triple helix structure, and it was rarely influenced by temperature. However, the triple helix conformation might take place in acid, alkali, and metal ions solution [15]. Statistics has shown that triple helix conformation was the most active spatial conformation of polysaccharides. Therefore, in this way, the excellent biological activity of IOPS might contribute to the triple helix conformation [77,82].

3.3. Surface Morphology

Atomic force microscopy (AFM) was used to observe IOPS spatial structure and surface morphology. Figure 2 exhibits the molecular morphology of the IOPS observed under AFM. With around 0.665 nm roughness, the contact area with water molecules was increased, which showed superior anti-fatigue activity [83].




Figure 2. AFM analysis of IOPS. Reproduced with permission [83].

4. Biological Activity

4.1. Antitumor Activity

The anticancer mechanism of IOPS mainly includes: Decreasing the expression of MMP-2, MMP-7, and MMP-9, increasing the expression of tissue metalloproteinase inhibitor 2 (TIMP-2), and decreasing the expression of NF- κ B in cancer cells [2,3,8,9,84–91].

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and Fluorescence activated cell sorting (FACS) is commonly used for cellular cytotoxicity studies. MTT assay assesses the effects of different drugs on cell viability, and a flow cytometry experiment can further quantify the extent of cell apoptosis by Annexin-V/PI Apoptosis Detection Kit; nonviable apoptotic or necrotic cells were generally defined to be situated in double positive (PI +/Annexin-V+) quadrant [92,93].

Researchers found that IOPS have obvious antitumor effects both in vitro and in vivo, despite that some different opinions on its mechanism. Some researchers think it stimulates the immune system while the others think the antioxidative ability prevents generation of cancer cells [17,94].

Zhang used MTT assay to validate IOPS inhibition of hepatic carcinoma cell line (SMMC7721) proliferation. The result showed a concentration correlation, IOPS in the range of 1.0–16.0 μ g/mL inhibition rate range from 43.6–69.2% [95].

Lee found that IOPS can effectively inhibit the migration and invasion of human non-small cell lung cancer A549 cells. Its possible mechanism might be that IOPS inhibits NF- κ B nuclear translocation and JNK/AKT phosphorylation in A549 cells, and inhibits the AKT/NF- κ B signaling pathway that reduces the expression level of matrix metalloproteinases (MMP); therefore, the invasion of human non-small cell lung cancer A549 cells was inhibited [96,97].

Zhang found that IOPS can induce apoptosis of ovarian cancer cell SKOV3. He speculated that the mechanism might be that IOPS reduces the mRNA expression of Bcl-xl gene by promoting the expression of p53 gene mRNA, thereby regulating the process of cell apoptosis [49].

Li verified IOPS inhibition effect on human cervical cancer cells (Hela), mouse bone marrow tumor cells (SP2), and human Chang's liver cells (Chang) through the MTT method [76]. Compared with 5-fluorouracil, the antitumor effect of IOPS was significant, and it was a promising antitumor substance. At a range of 10–1000 μ g/mL IOPS, proliferation on Hela, SP2, and Chang cells were obviously inhibited. The growth inhibition rates were from 4.78% to 46.54%, 2.89% to 44.90%, 3.56% to 22.56%, respectively. And it showed a concentration-dependent relationship. There was a significant difference in the growth inhibition rate between each concentration ($p < 0.01$).

Chen also used the MTT method to study the inhibitory effect of IOPS on Jurkat and Daudi tumor cells in vitro, and the results showed that IOPS had a significant in vitro inhibitory effect on the proliferation of tumor cells Jurkat and Daudi ($p < 0.01$), and it had dose-dependent, and its maximum inhibition rates reached 71.84% and 75.14%, respectively [15]. Besides, he established a Jurkat tumor-bearing nude mice model to study in vivo effect of IOPS. The results showed that given a daily dose of 50–100 mg/kg IOPS for

10 days, the tumor inhibition rate varied from 43.52% to 57.48%. He also studied the release of Cytc and the expression of caspase-3 enzyme via Western blotting. By the aid of DNA ladders gel electrophoresis analysis, the mechanism of IOP3a-induced tumor cell apoptosis was determined: by stimulating tumor cell mitochondria to release Cytc, caspase-3 was activated and endogenous was activated. Endonuclease caused a DNA cleavage to achieve its antitumor effect [98].

Lin Yan studied the antitumor activity of IOPS by constructing a Kunming mouse S180 tumor-bearing model, and found that the inhibition rate was positively correlated with the IOPS dose. Among them, the inhibition rate of *Inonotus obliquus* intracellular and extracellular polysaccharide on S180 were 30.13–41.07%, 23.29–36.73%, respectively. In addition, compared with the control group, *Inonotus obliquus* extracellular polysaccharide could significantly increase the thymus index and spleen index of S180 tumor-bearing mice (immune indicators) [99].

Besides, Jiang's research demonstrated that IOPS could significantly inhibit allograft tumor growth of the LLC1 cells with increased apoptosis at 50 mg/kg dosage [100]. Li tested the efficacy of IOPS by using a mouse model of Colitis-Associated Cancer (CAC) induced by azoxymethane and dextran sulfate sodium (AOM/DSS) to confirm that IOPS inhibited the proliferation of SW620 colorectal cancer cells [22].

IOPS on human osteosarcoma MG-63 cells and U2OS cells' s proliferation, invasion, migration, and apoptosis was studied in vitro by CCK-8 assays, cell scratch assays, trans-well assays, and flow cytometry. Moreover, 320 $\mu\text{g}/\text{mL}$ IOPS significantly inhibited proliferation, decreased migration and invasion ability, and increased apoptosis rate ($p < 0.05$) as IOPS could significantly inhibit the activation of the Akt/mTOR and NF- κB signaling pathway ($p < 0.05$) [101].

Yang obtained C-OWC contained with about 70% *Inonotus obliquus* polysaccharide by water extraction and ethanol precipitation. It could increase the mRNA expression of Bax, P21 and Bid genes in human liver cancer cells HepG2, while significantly reducing the expression of Bcl-2 genes. The mechanism of action might be that C-OWC increased the expression of P21 gene mRNA, and blocked the cell cycle of HepG2 cells in the G0/G1 phase, thereby inhibiting cell division and proliferation. Meanwhile it increased the mRNA expression of Bax and Bid genes in cells and reduces Bcl-2 gene mRNA expression, thereby inducing HepG2 cell apoptosis [102]. The diagram of possible mechanisms is shown in Figure 3 and they are concluded in Table 4.




Figure 3. Possible anticancer mechanism of IOPS.

Table 4. Anticancer studies of IOPS.

| Cancer/Tumor Type | Concentration/Dose | Inhibition Rate | Mechanism | References |
|---|-----------------------------|--|---|------------|
| Hepatic carcinoma cell line (SMMC7721) | 1.0–16.0 µg/mL | 43.6–69.2% | N/A | [95] |
| Human non-small cell lung cancer cells (A549) | 100 µg/mL | 26% | NF-κB nuclear translocation (–), JNK/AKT phosphorylation (–), AKT/NF-κB (–), MMP expression level (–), Invasion (–) | [45,96,97] |
| Ovarian cancer cells (SKOV3) | 160 µg/mL | 23.94% | p53 gene mRNA expression (+), Bcl-xl gene mRNA expression (–), regulating cell apoptosis | [49] |
| Human cervical cancer cells (Hela) | 10–1000 µg/mL | 4.78–46.54% | N/A | [76] |
| Mouse bone marrow tumor cells (SP2) | 10–1000 µg/mL | 2.89–44.90% | N/A | [76] |
| Human Chang's liver cells (Chang) | 10–1000 µg/mL | 3.56–22.56% | N/A | [76] |
| Human T lymphocytic leukemia cells (Jurkat) | 200 µg/mL 50–100 mg/kg·d | 71.84% 43.52–57.48% | Tumor cell mitochondria release CytC(+), caspase-3 (+), endogenous (+), DNA cleavage | [15,98] |
| Human B lymphocyte tumor cells (Daudi) | 200 µg/mL | 75.14% | N/A | [15] |
| Kunming mouse S180 tumor | 200 mg/kg·d | 41.07% (intracellular polysaccharide) 36.73% (extracellular polysaccharide) | N/A | [99] |
| Human cervical cancer cells (Hela) | 200 µg/mL | 57.7% | N/A | [103] |
| Osteosarcoma cells (MG-63 and U2OS) | 320 µg/mL | 22.3% (MG-63) 23.64% (U2OS) | Akt/mTOR (–), NF-κB (–) | [101] |

(+): improve or promote; (–): inhibit or reduce. N/A: information was not available.

4.2. Hypoglycemic and Hypolipidemic Activities

The main mechanism of IOPS hypolipidemic activities may be attributed to the increase of lecithin-cholesterol acyl transferase (LCAT) activity, which promotes the synthesis of high-density lipoprotein cholesterol (HDL-C2), and transfers the free cholesterol in peripheral tissues to the liver, catalyzes the hydrolysis of triglycerides (TG) into glycerol and fatty acids, and promotes the conversion of high-density lipoprotein 3-cholesterol (HDL3-C) into HDL-C2, promotes the reverse transport and metabolism of cholesterol, thereby reducing serum total cholesterol (TC) content [104]. The hypoglycemic activity of polysaccharides is closely related to its structure. It could be affected by monosaccharide composition, molecular weight, branched chain structure, high-level structure, etc. Existing studies have found that the mechanisms of polysaccharides for hypoglycemic activity mainly include regulation of enzyme activity, liver glucose metabolism, intestinal flora, protection and reparation of pancreatic islet cells, and improvement of insulin sensitivity [105–109].

Wang and Zhang investigated the anti-diabetic effects and the potential mechanism of IOPS in vivo and found that IOPS ameliorated insulin resistance and lipid metabolism disorders in streptozotocin-induced type 2 diabetic mice. The possible hypoglycemic and hypolipidemic mechanism might supposedly be via the regulation of the PI3K/Akt

and AMPK/ACC signal pathways [40,64]. As Wang's results had shown, in comparison with controlled diabetic mice, 900 mg/kg oral administration of IOPS reduced 28% serum glucose in mice, significantly restored the body and fat weight, and lowered fasting blood glucose levels, improved glucose tolerance ability and, thus, increased the level of hepatic glycogen and improved insulin resistance. Zhang found that given *I. obliquus* extract at 500 mg/kg orally, the blood glucose and insulin resistance of diabetic mice significantly alleviated while the cholesterol transportation in the liver enhanced, liver glycogen content and high-density lipoprotein cholesterol (HDL-C) levels increased with significant decline in total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) levels. Zhang supposed that the upregulated protein expression levels of phosphatidylinositol-3 kinase (PI3K), p-protein kinase B (Akt), p-adenosine monophosphate activated protein kinase (AMPK) and p-acetyl-CoA carboxylase (ACC) with down-regulating in fatty acid synthase (FAS) and sterol regulatory element-binding protein-1c (SREBP-1c) also contributed to the hypoglycemic effects of IOPS [64].

α -Amylase and α -glucosidase are enzymes that promote the breaking of α -1,4-glycosidic bonds in starch, maltose, sucrose and oligosaccharides and hydrolyze them into monosaccharide that are easy to digest and be absorbed by the human body, such as glucose [106]. This caused the postprandial blood glucose levels of diabetic patients to increase and insulin sensitivity to be reduced, even lead them to serious complications and aggravate the condition [110]. Chen et al. found that IOPS could reduce the absorption of carbohydrates by inhibiting the activity of intestinal α -amylase and α -glucose, effectively reducing postprandial blood glucose levels, repairing islet damage, and improving complications [111]. Cong Wang investigated the simulated digestion of *Inonotus obliquus* polysaccharide UIOPS-1 in vitro. The digested polysaccharide (UIOPS-1I) after digestion could inhibit α -amylase up to 37.96% at a concentration of 200 μ g/mL, which was significantly higher than the initial state of UIOPS-1 ($p < 0.001$). He speculated that it might be caused by the changes in monosaccharide composition and the decrease in molecular weight [38,40,54,55].

Through in vitro experiments, Xue found that IOEP1 and IOEP2 strongly increased HepG2 cells' glucose consumption and insulin-resistant HepG2 cells, which proved that IOEP1 and IOEP2 might be suitable anti-diabetes agents in functional foods and natural drugs [39]. With significant anti-diabetic effects, IOPS might be a promising candidate for the clinical treatment of diabetes mellitus [112]. The possible hypoglycemic mechanism of IOPS are shown in Figure 4.




Figure 4. Possible hypoglycemic mechanism of IOPS.

4.3. Antioxidant Activity

The human body continuously produces various reactive oxygen free radicals during the oxidative metabolism process of life activities, which may easily cause oxidative damage to DNA and further cause cancer, arteriosclerosis, aging, and other diseases. Polysaccharides and polysaccharide metal ion complexes have excellent antioxidant activity, and their antioxidant mechanisms mainly include: direct capture or removal of active oxygen such as OH, O₂, and H₂O₂ inhibit the progress of the oxidation reaction, thereby blocking the initiation of the lipid peroxidation reaction; complexes of metal ions such as Fe²⁺ and Cu²⁺ that are necessary for the production of active oxygen inhibit the production of active oxygen; promote the production of SOD, CAT, GSH-Px and other antioxidant enzymes release or increase their activity, which indirectly exerts antioxidant effects [20,113–117].

IOPS antioxidant activities were frequently investigated by hydroxyl radical assay, superoxide radical assay, and ferric-reducing antioxidant power assay. Raw 264.7 cell models are often built to assess the in vitro activity [9,10,59,69,117–120]. The results showed that IOPS exhibited antioxidant activities, and the higher the content of uronic acid and proteinous substances, the stronger the antioxidant activities of polysaccharides [121–126]. Besides, molecular weights of polysaccharides also influence their antioxidant activities. IOP3a and IOP4 showed higher antioxidant properties than IOP1b, IOP2a, and IOP2c [126].

Sim's study revealed that IOPS protection against H₂O₂-induced oxidative damage in RINm5F pancreatic β cells at 25–100 μg/mL [127]. Chen found that 1 mg/mL IOPS scavenged 49.72% hydroxyl radical and IC₅₀ for DPPH scavenging was 0.62 ± 0.01 μg/mL [120,128]. IC₅₀ of superoxide anion scavenging was 425 μg/mL [122].

Mu investigated IOPS antioxidant properties via reactive species (ROS), 1,1'-Diphenyl-2-picrylhydrazyl (DPPH) radical, hydroxyl radical and superoxide anion radical, as well as their protective effects on H₂O₂-induced PC12 cell death. Results indicated that IOPS could scavenge all ROS and rescue PC12 cell viability from 38.6% to 79.8% and 83.0% at a concentration of 20 μg/mL [125].

4.4. Anti-Fatigue Activity

The mice swimming model is frequently the test model [129]. Zhong used 64 male mice and Zhang used 40 Kunming mice (four weeks old) for an anti-fatigue activity study. Four groups were given polysaccharide fractions 1 of *Inonotus obliquus* (PIO-1), polysaccharide fractions 2 of *Inonotus obliquus* (PIO-2), polysaccharide fractions 3 of *Inonotus obliquus* (PIO-3) and saline (control group) orally for 30 days, and mice were submitted to the forced-swimming test [83,129]. Total duration of climbing, swimming, and immobility in the last 5 min of the 6 min test session, blood lactic acid (BLA), urea nitrogen (BUN), and lactic dehydrogenase (LDH) were collected for analysis. Total integrated optical density (IOD) that represents the 5-HT expression levels in brains was determined. As Figures 5 and 6 have shown, the forced swimming test showed that the 50 mg/kg dose of PIO-1 could increase the climbing time and swimming time and reduce the immobile time, which indicated that PIO-1 reduced blood lactic acid (BLA), urea nitrogen (BUN), and lactate dehydrogenase (LDH) levels and significantly reduced the 5-HT concentration (total integrated optical density (IOD) representing the expression levels) in the mouse brain.




Figure 5. Effect of polysaccharide fractions on mice force swimming test. (A) Climbing duration of mice. (B) Swimming time of mice. (C) Duration of immobility. All bars represent mean values with vertical lines indicating S.E.M. Number of animals = 10. * $p < 0.05$ vs. control group. ** $p < 0.01$ vs. control group (1—Saline-treated group; 2—PIO-1-treated group; 3—PIO-2-treated group; and 4—PIO-3-treated group).




Figure 6. Effect of polysaccharide fractions on 5-HT concentrations in mice. Histological examination on 5-HT concentrations in mice (A) Saline-treated group; (B) PIO-1 treated group; (C) PIO-2 treated group; and (D) PIO-3 treated group) H&E staining results; (E) all bars represent mean values with vertical lines indicating S.E.M. Number of animals = 10. * $p < 0.01$ vs. control group (1—Saline-treated group; 2—PIO-1 treated group; 3—PIO-2 treated group; and 4—PIO-3 treated group). Reproduced with permission [83].

Reproduced with permission [83].

4.5. Antiviral Effect

A virus is a submicroscopic infectious agent that infects all types of life forms, from animals and plants to microorganisms, including bacteria and archaea [130]. The virus has brought great harm to human society; especially the Covid-19 virus that broke out in Wuhan in 2019 and has caused 2,681,790 deaths as of 18 March 2021, according to Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) [131]. Therefore, the research on antiviral drugs is of great significance.

Currently, there are relatively few studies on the antiviral mechanism of *Inonotus obliquus*, and further research is needed. It was reported that IOPS could inhibit the induction of NO and other similar cytokines, a phenomenon that had been associated with Covid-19 [132,133]. By using cell models of feline calicivirus (FCV) in vitro, Tian revealed the mechanism of IOPS treatment was that it might induce its inhibitory actions directly on virus particles through blocking viral binding/absorbing, and this demonstrated that IOPS might be a potential broad-spectrum antiviral drug against feline viruses [134]. Pan investigated the antiviral mechanisms of AEIO (aqueous extract from *Inonotus obliquus*, contains IOPS), and unlike nucleoside analog antiherpetics, it could effectively prevent the entry of HSV-1 by acting on viral glycoproteins and lead to the prevention of membrane fusion [135].

According to Ichimura et al., a high-molecular-weight water-soluble lignin derivative extracted from *Inonotus obliquus* by boiling water extraction had significant inhibitory activity on HIV-1 protease. He speculated that the possible mechanism might be that this lignin derivative was adsorbed on the protease and inhibited the reverse transcriptase of HIV, thus, achieving the effect of inhibiting the reproduction of HIV. In contrast, those low-molecular-weight polyphenols and low-molecular-weight lignin could not inhibit the protease [136].

4.6. Immunomodulatory Activity

Fan found that polysaccharide ISP2a significantly enhanced the lymphocyte proliferation and increased the production of TNF- α , demonstrating IOPS to be a potential application as natural antitumor agent with immunomodulatory activity [36,46,137].

Won investigated the immune stimulating activity of IOPS and the signaling pathway of IOPS-mediated macrophage activation in RAW264.7 macrophage cells [137]. It was found that IOPS effectively promoted macrophage activation through the MAPK and NF- κ B signaling pathways and potentially regulated the immune response, as IOPS promoted NO/ROS production, secreted more TNF- α and uptook phagocytic in macrophages, cell proliferation, comitogenic effect and IFN- γ /IL-4 secretion in mouse splenocytes.

The activation of NLRP3 inflammasome can cause the overexpression and secretion of inflammation-related cytokines, and mediate the occurrence of inflammation. When the activation of NLRP3 inflammasome is inhibited, the inflammation-related diseases involved in it may be improved. In Lipopolysaccharide (LPS)-induced macrophage inflammation, Zheng found that IOPS can inhibit the expression of IL-18 and IL-1 β by inhibiting the phosphorylation of NF- κ B-p65 ($p < 0.05$) [22,138,139].

By IOPS oral administration, in vivo growth of melanoma tumor was suppressed in tumor-bearing mice. Harikrishnan revealed that IOPS could positively enhance the innate immune system that effectively promote the health status of kelp grouper against *V. harveyi* infection [140]. The possible anti-inflammation mechanism is shown in Figure 7.




Figure 7. Possible anti-inflammation mechanism of IOPS.

4.7. Other Bioactivities

Hu revealed that IOPS could regulate gut microbiota of chronic pancreatitis in mice [141]. Chen studied IOPS' anti-inflammatory effect, and the results showed that IOPS alleviated inflammatory responses by inhibiting JAK-STAT signaling pathways that regulate the release of T Helper subsets, and could alleviate dextran sodium sulfate-induced chronic murine intestinal inflammation in mice at 100 mg/kg [142].

Toxoplasma gondii (*T. gondii*) infection caused liver injury model in mice are frequently applied for hepatoprotective effects. Xu studied IOPS hepatoprotective effects and mechanism in vivo via this model [143]. The results showed that IOPS treatment significantly decreased the liver coefficient, alanine aminotransferase (ALT) level, aspartate aminotransferase (AST), malondialdehyde (MDA) and nitric oxide (NO), and increased the contents of antioxidant enzyme superoxide dismutase (SOD) and glutathione (GSH). The protection was partly due to its anti-inflammatory effects through inhibiting the TLRs/NF- κ B signaling axis and the activation of an antioxidant response by inducing the Nrf2/HO-1 signaling.

Chen et al. optimized the extraction process and obtained IOPS composed with mannose, glucose, galactose, and xylose of 1.00:4.49:1.00:0.85 mass ratio. Comparing with traditional extraction methods, their patent has shown the modified preparation method: washing the water extract with absolute ethanol and acetone three times and adding 5:1 (*v/v*) chloroform-*n*-butanol solution, followed by dialyzing with 3500 Da molecular weight dialysis bag in deionized water for 48 h, and then the collected dialysate was freeze-dried. The obtained IOPS could treat atopic dermatitis, food allergy, allergic rhinitis or asthma, especially for systemic allergies caused by OVA in animal experiments; thus, IOPS could be developed into an anti-allergic drug [144].

5. Toxicity of IOPS

Despite that most polysaccharides are low-toxic with no significant side effects, it is still necessary to evaluate the potential risks and toxicity of polysaccharides in detail before clinical research [104]. Usually, the toxicity is studied via MTT assay or an animal

model. Zheng studied the cytotoxicity of IOPS toward Raw264.7 cells via MTT assay. Different concentrations of IOPS and PBS (control group) were added to a 96-well plate, and RAW264.7 cells were incubated for 24 h; there were no significant difference between the control group and the IOPS group in cell survival rate. The results also showed that 20–160 µg/mL of IOPS administration was safe and would not produce drug toxicity [138]. Dr. Gao studied the in vitro cytotoxicity of *Inonotus obliquus* ethyl acetate fraction towards normal hepatic cells. The results showed that *Inonotus obliquus* ethyl acetate was nontoxic to L02 cells and could protect L02 cells from oxidative damage caused by hydrogen peroxide. However, the ethyl acetate fraction only contained part of IOPS, not pure IOPS [145]. Cong Wang studied the sub-acute toxicity of *Inonotus obliquus* polysaccharides-chromium (III) complex in normal mice. His result confirmed that high dose administration of IOPS had neither an obvious influence on serum profiles levels nor an antioxidant ability, as the organ tissues of the toxicity group maintained organization and integrity after having been given a high dose of IOPS chromium (III) complex [146]. Briefly, 20 mice were randomly separated into two groups; the normal control group (NC) received normal saline, while the toxicity group (TC) received IOPS chromium (III) complex at a daily dose of 1500 mg/kg. All the mice were sacrificed after four weeks' administration, and the liver, pancreases, kidney, heart, thymus, and spleen were collected and weighted, and then the liver, pancreases, and kidney were fixed with 10% formalin for histological analysis. Both these results suggested that IOPS had the potential to be a good candidate for functional food or even pharmaceuticals agents.

6. Application

For centuries, *Inonotus obliquus* (Chaga mushroom) has been used in Kiev to cure lip tumor, and it is a traditional medicine in Siberia [147]. Nowadays, a growing number of *Inonotus obliquus* related functional foods are developed. As Liu's patent CN104366193-A has shown, healthcare food composed of IOPS will be used for preventing and treating diabetes, reducing blood fat, removing free radicals, protecting the heart, and regulating immune function.

Owing to its wide range of pharmacological activities, including hypoglycemic activity, improving immunity, anti-fatigue activity, and various beneficial effects, IOPS is used in functional and health products in Russia, China, and the US. Reviewing the existing products on e-commerce platforms such as Amazon and Taobao, we found that most commercial applications are health products, tea, and tincture. The existing and potential IOPS applications are listed in Tables 5 and 6. Some healthy food products include Sorlife Chaga capsules, IOPS tea, tablets, and Chaga briquettes, which are listed on e-commerce platforms, where they were called natural insulin. To improve the quality demands of customers and enhancing the manufacturer's reputation, the manufacturer might implement ISO22000:2018 and the HACCP methodology [148].

Table 5. Existing IOPS application.

| Application | Function | Brand |
|----------------|-------------------------------|--------------------|
| Health product | Hypoglycemic | Komsomlski |
| Health product | Enhance immunity | Wonder Land Herbs |
| Health product | Hypoglycemic | Sorlife |
| Tea | Enhance immunity | Johncan production |
| Tea | Enhance immunity, antioxidant | Atomic nature |
| Tincture | | Florida Herbs |

Table 6. Potential IOPS application.

| Application | Function | References |
|-------------------|----------------------------------|------------|
| Beverage | Hypoglycemic | [149] |
| Healthcare food | Preventing and treating diabetes | [150] |
| Functional yogurt | Enhance immunity, hypoglycemic | [151] |
| Drug | Anti-allergic | [144] |

7. Conclusions and Future Perspectives

As more and more patients tend to find alternative therapies for cancer and diabetes, the awareness towards seeking natural products has increased in both academia and in society. IOPS exhibited enormous potential in immunity enhancement, and antitumor, antioxidant, anti-fatigue, hypoglycemic, and hypolipidemic activity, providing an alternative way for treatment of cancer and diabetes. The present review of *Inonotus obliquus* polysaccharides mainly focused on the recent advances in the isolation, purification, physicochemical characterization and bioactivities. By applying new extraction method, the yield of IOPS can be significantly increased. IOPS exhibited significant hypoglycemic, hypolipidemic, antioxidant, and anti-fatigue activity, and cytotoxicity toward multiple cancer cells, including hepatic carcinoma cells, human non-small cell lung cancer cells, ovarian cancer cells, human cervical cancer cells, etc. The low-toxic property and no obvious side effects make it more attractive.

Although the development of IOPS has achieved advanced progress in the last decade, some problems still cannot be ignored. Due to the variations of habitat environment and extraction methods, the composition and content of the obtained polysaccharides are not the same. Thus, the establishment of planting and extraction standard is of great importance. Furthermore, despite that more and more remarkable pharmacological advances are being made, the present commercial applications are still limited to several functional foods. On the one hand, deep investigations in precise mechanisms underlying their bioactivities and the structure-activity relationships (SAR) are crucial. On the other hand, further investigations that focus on toxicity and potential risks are also to be conducted to provide solid scientific and theoretical guidance for synthesizing IOPS derivatives with enhanced biological activity and less side effects. Meanwhile, the development of related products, especially commercial applications are also encouraged, in that more and more people can benefit from the multiple bioactivities of natural polysaccharides.

Author Contributions: H.C. conceived the idea, Y.L. wrote the review article, and Y.J., Z.X., N.L., J.L. have edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: The APC was funded by Tianjin Municipal Science and Technology Foundation (Grant No. 18PTZWHZ00190).

Data Availability Statement: Data are contained within the article.

Acknowledgments: Special thanks to editor and reviewers' s kindly suggestions and comments. Thanks Li Liu for her kindly guidance and help in drawing schematic diagrams.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. WHO. *World Health Statistics 2020: Monitoring Health for the SDGs, Sustainable Development Goals*; World Health Organization: Geneva, Switzerland, 2020.
2. Centers for Disease Control and Prevention. *National Diabetes Statistics Report, 2020*; U.S. Dept of Health and Human Services: Washington, DC, USA, 2020.
3. American Cancer Society. *Cancer Facts & Figures 2021*. Available online: <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html> (accessed on 15 March 2021).

4. Hazhir, N.; Chekin, F.; Raoof, J.B.; Fathi, S. Anticancer activity of Doxorubicin conjugated to polymer/carbon based-nanohybrid against MCF-7 breast and HT-29 colon cancer cells. *Int. J. Nano Dimens.* **2021**, *12*, 11–19.
5. Malik, Z.; Parveen, R.; Parveen, B.; Zahiruddin, S.; Aasif Khan, M.; Khan, A.; Massey, S.; Ahmad, S.; Husain, S.A. Anticancer potential of andrographolide from *Andrographis paniculata* (Burm.f.) Nees and its mechanisms of action. *J. Ethnopharmacol.* **2021**, *272*, 113936. [[CrossRef](#)] [[PubMed](#)]
6. Zeng, Y.; Xiang, Y.; Sheng, R.; Tomas, H.; Rodrigues, J.; Gu, Z.; Zhang, H.; Gong, Q.; Luo, K. Polysaccharide-based nanomedicines for cancer immunotherapy: A review. *Bioact. Mater.* **2021**, *6*, 3358–3382. [[CrossRef](#)] [[PubMed](#)]
7. Zapora, E.; Wolkowycski, M.; Bakier, S.; Zjawiony, J.K. *Phellinus igniarius*: A Pharmacologically Active Polypore Mushroom. *Nat. Prod. Commun.* **2016**, *11*, 1043–1046. [[CrossRef](#)] [[PubMed](#)]
8. Baek, J.; Roh, H.S.; Baek, K.H.; Lee, S.; Lee, S.; Song, S.S.; Kim, K.H. Bioactivity-based analysis and chemical characterization of cytotoxic constituents from Chaga mushroom (*Inonotus obliquus*) that induce apoptosis in human lung adenocarcinoma cells. *J. Ethnopharmacol.* **2018**, *224*, 63–75. [[CrossRef](#)]
9. Ma, L.S.; Chen, H.X.; Dong, P.; Lu, X.M. Anti-inflammatory and anticancer activities of extracts and compounds from the mushroom *Inonotus obliquus*. *Food Chem.* **2013**, *139*, 503–508. [[CrossRef](#)] [[PubMed](#)]
10. Niu, H.; Song, D.; Mu, H.B.; Zhang, W.X.; Sun, F.F.; Duan, J.Y. Investigation of three lignin complexes with antioxidant and immunological capacities from *Inonotus obliquus*. *Int. J. Biol. Macromol.* **2016**, *86*, 587–593. [[CrossRef](#)] [[PubMed](#)]
11. Saar, M. Fungi in Khanty folk medicine. *J. Ethnopharmacol.* **1991**, *31*, 175–179. [[CrossRef](#)]
12. Zheng, W.F.; Miao, K.J.; Liu, Y.B.; Zhao, Y.X.; Zhang, M.M.; Pan, S.Y.; Dai, Y.C. Chemical diversity of biologically active metabolites in the sclerotia of *Inonotus obliquus* and submerged culture strategies for up-regulating their production. *Appl. Microbiol. Biotechnol.* **2010**, *87*, 1237–1254. [[CrossRef](#)]
13. Lee, M.W.; Hur, H.; Chang, K.C.; Lee, T.S.; Ka, K.H.; Jankovsky, L. Introduction to Distribution and Ecology of Sterile Conks of *Inonotus obliquus*. *Mycobiology* **2008**, *36*, 199–202. [[CrossRef](#)] [[PubMed](#)]
14. Babitskaya, V.G.; Shcherba, V.V.; Ikonnikova, N.V. Melanin complex of the fungus *Inonotus obliquus*. *Appl. Biochem. Microbiol.* **2000**, *36*, 377–381. [[CrossRef](#)]
15. Yiyong, C. *Study on Purification, Structure and Anti-Tumor Mechanism of Inonotus Obliquus Polysaccharide*; Jiangnan University: Wuxi, China, 2010.
16. Chen, Y.Y.; Gu, X.H.; Huang, S.Q.; Li, J.W.; Wang, X.; Tang, J. Optimization of ultrasonic/microwave assisted extraction (UMAE) of polysaccharides from *Inonotus obliquus* and evaluation of its anti-tumor activities. *Int. J. Biol. Macromol.* **2010**, *46*, 429–435. [[CrossRef](#)]
17. Chen, Y.Y.; Huang, Y.R.; Cui, Z.M.; Liu, J.J. Purification, characterization and biological activity of a novel polysaccharide from *Inonotus obliquus*. *Int. J. Biol. Macromol.* **2015**, *79*, 587–594. [[CrossRef](#)] [[PubMed](#)]
18. Zhao, Y.X.; Zheng, W.F. Deciphering the antitumoral potential of the bioactive metabolites from medicinal mushroom *Inonotus obliquus*. *J. Ethnopharmacol.* **2021**, *265*, 113321. [[CrossRef](#)]
19. Yu, J.; Xiang, H.Y.; Xie, Q.H. The difference of regulatory effect of two *Inonotus obliquus* extracts on high-fat diet mice in relation to the fatty acid elongation function of gut microbiota. *Food Sci. Nutr.* **2021**, *9*, 449–458. [[CrossRef](#)] [[PubMed](#)]
20. Tanye, X. Optimization of Extraction of Polysaccharides from *Inonotus obliquus* by Response Surface Methodology and Antioxidant Activity. *Food Res. Dev.* **2021**, *42*, 143–148.
21. Lu, X.H.; Wang, M.Y.; Zhao, Z.Z.; Hu, J.R.; Zhang, J.S.; Liu, P. Effect of Different Pretreatment of Birch Sawdust on the Production of Active Polysaccharides by *Inonotus obliquus* Under Submerged Fermentation and Its Structural Mechanism. *Appl. Biochem. Biotech.* **2021**, 1–13. [[CrossRef](#)]
22. Li, J.W.; Qu, C.; Li, F.F.; Chen, Y.F.; Zheng, J.J.; Xiao, Y.; Jin, Q.X.; Jin, G.H.; Huang, X.Z.; Jin, D. *Inonotus obliquus* Polysaccharide Ameliorates Azoxymethane/Dextran Sulfate Sodium-Induced Colitis-Associated Cancer in Mice via Activation of the NLRP3 Inflammasome. *Front. Pharm.* **2021**, *11*, 2505. [[CrossRef](#)]
23. Xu, L.; Yu, Y.F.; Sang, R.; Ge, B.J.; Wang, M.; Zhou, H.Y.; Zhang, X.M. *Inonotus obliquus* polysaccharide protects against adverse pregnancy caused by *Toxoplasma gondii* infection through regulating Th17/Treg balance via TLR4/NF-kappa B pathway. *Int. J. Biol. Macromol.* **2020**, *146*, 832–840. [[CrossRef](#)]
24. Wold, C.W.; Gerwick, W.H.; Wangenstein, H.; Inngjerdingen, K.T. Bioactive triterpenoids and water-soluble melanin from *Inonotus obliquus* (Chaga) with immunomodulatory activity. *J. Funct. Foods* **2020**, *71*. [[CrossRef](#)]
25. Wang, Y.; Ouyang, F.; Teng, C.; Qu, J. Optimization for the extraction of polyphenols from *Inonotus obliquus* and its antioxidation activity. *Prep. Biochem. Biotechnol.* **2020**. [[CrossRef](#)]
26. Du, N.; Wu, K.; Zhang, J.; Wang, L.; Pan, X.; Zhu, Y.; Wu, X.; Liu, J.; Chen, Y.; Ye, Y.; et al. *Inonotus obliquus* B regulates M1 to M2 macrophage polarization through sirtuin-1/endoplasmic reticulum stress axis. *Int. Immunopharmacol.* **2021**, *96*, 107603. [[CrossRef](#)] [[PubMed](#)]
27. Maza, P.A.M.A.; Lee, J.-H.; Kim, Y.-S.; Sun, G.-M.; Sung, Y.-J.; Ponomarenko, L.P.; Stonik, V.A.; Ryu, M.; Kwak, J.-Y. Inotodiol From *Inonotus obliquus* Chaga Mushroom Induces Atypical Maturation in Dendritic Cells. *Front. Immunol.* **2021**, *12*. [[CrossRef](#)]
28. Zou, C.-X.; Dong, S.-H.; Hou, Z.-L.; Yao, G.-D.; Lin, B.; Huang, X.-X.; Song, S.-J. Modified lanostane-type triterpenoids with neuroprotective effects from the fungus *Inonotus obliquus*. *Bioorganic Chem.* **2020**, *105*. [[CrossRef](#)] [[PubMed](#)]
29. Kim, J.; Yang, S.C.; Hwang, A.Y.; Cho, H.; Hwang, K.T. Composition of Triterpenoids in *Inonotus obliquus* and Their Anti-Proliferative Activity on Cancer Cell Lines. *Molecules* **2020**, *25*, 4066. [[CrossRef](#)] [[PubMed](#)]

30. Lin, P.; Yan, Z.-F.; Li, C.-T. Effects of Exogenous Elicitors on Triterpenoids Accumulation and Expression of Farnesyl Diphosphate Synthase Gene in *Inonotus obliquus*. *Biotechnol. Bioproc. Eng.* **2020**, *25*, 580–588. [[CrossRef](#)]
31. Nosik, D.N.; Nosik, N.N.; Teplyakova, T.V.; Lobach, O.A.; Kiseleva, I.A.; Kondrashina, N.G.; Bochkova, M.S.; Ananko, G.G. Antiviral activity of extracts of basidiomycetes and humic compounds substances against Human Immunodeficiency Virus (Retroviridae: Orthoretrovirinae: Lentivirus: Human immunodeficiency virus 1) and Herpes Simplex Virus (Herpesviridae: Simplexvirus: Human alphaherpesvirus 1). *Vopr. Virusol.* **2020**, *65*, 276–283.
32. Teplyakova, T.V.; Ilyicheva, T.N.; Kosogova, T.A.; Wasser, S.P. Medicinal Mushrooms against Influenza Viruses. *Int. J. Med. Mushrooms* **2021**, *23*, 1–11. [[CrossRef](#)] [[PubMed](#)]
33. Sysoeva, M.A.; Khabibrakhmanova, V.R.; Urazlina, L.N. Nutrient Medium for Cultivation of Chaga Fungus. RU2019124646, 31 July 2019.
34. Teplyakova, T.V.; Ilyicheva, T.N.; Markovich, N.A. Prospects for the Development of Anti-Influenza Drugs Based on Medicinal Mushrooms (Review). *Appl. Biochem. Microbiol.* **2020**, *56*, 489–496. [[CrossRef](#)]
35. Haixia, C. Relationship between structure and effect of active polysaccharide. *Sci. Focus* **2013**, *8*, 53–55.
36. Wold, C.W.; Kjeldsen, C.; Corthay, A.; Rise, F.; Christensen, B.E.; Duus, J.O.; Inngjerdigen, K.T. Structural characterization of bioactive heteropolysaccharides from the medicinal fungus *Inonotus obliquus* (Chaga). *Carbohydr. Polym.* **2018**, *185*, 27–40. [[CrossRef](#)] [[PubMed](#)]
37. Wang, M.Y.; Zhao, Z.Z.; Zhou, X.; Hu, J.R.; Xue, J.; Liu, X.; Zhang, J.S.; Liu, P.; Tong, S.S. Simultaneous Use of Stimulatory Agents to Enhance the Production and Hypoglycaemic Activity of Polysaccharides from *Inonotus obliquus* by Submerged Fermentation. *Molecules* **2019**, *24*, 4400. [[CrossRef](#)]
38. Wang, C.; Li, W.; Chen, Z.; Gao, X.; Yuan, G.; Pan, Y.; Chen, H. Effects of simulated gastrointestinal digestion in vitro on the chemical properties, antioxidant activity, alpha-amylase and alpha-glucosidase inhibitory activity of polysaccharides from *Inonotus obliquus*. *Food Res. Int.* **2018**, *103*, 280–288. [[CrossRef](#)]
39. Xue, J.; Tong, S.S.; Wang, Z.R.; Liu, P. Chemical Characterization and Hypoglycaemic Activities In Vitro of Two Polysaccharides from *Inonotus obliquus* by Submerged Culture. *Molecules* **2018**, *23*, 3261. [[CrossRef](#)] [[PubMed](#)]
40. Wang, J.; Wang, C.; Li, S.; Li, W.; Yuan, G.; Pan, Y.; Chen, H. Anti-diabetic effects of *Inonotus obliquus* polysaccharides in streptozotocin-induced type 2 diabetic mice and potential mechanism via PI3K-Akt signal pathway. *Biomed. Pharm.* **2017**, *95*, 1669–1677. [[CrossRef](#)]
41. Zhang, Y.B.; Zhao, Y.; Cui, H.F.; Cao, C.Y.; Guo, J.Y.; Liu, S. Comparison of Hypoglycemic Activity of Fermented Mushroom of *Inonotus obliquus* Rich in Vanadium and Wild-Growing *I. obliquus*. *Biol. Trace Elem. Res.* **2011**, *144*, 1351–1357. [[CrossRef](#)] [[PubMed](#)]
42. Szychowski, K.A.; Rybczynska-Tkaczyk, K.; Tobiasz, J.; Yelnytska-Stawasz, V.; Pomianek, T.; Gminski, J. Biological and anticancer properties of *Inonotus obliquus* extracts. *Process Biochem.* **2018**, *73*, 180–187. [[CrossRef](#)]
43. Gery, A.; Dubreule, C.; Andre, V.; Rioult, J.P.; Bouchart, V.; Heutte, N.; de Pecoulas, P.E.; Krivomaz, T.; Garon, D. Chaga (*Inonotus obliquus*), a Future Potential Medicinal Fungus in Oncology? A Chemical Study and a Comparison of the Cytotoxicity Against Human Lung Adenocarcinoma Cells (A549) and Human Bronchial Epithelial Cells (BEAS-2B). *Integr. Cancer* **2018**, *17*, 832–843. [[CrossRef](#)]
44. Smith, A.; Javed, S.; Barad, A.; Myhre, V.; Li, W.M.; Reimer, K.; Massicotte, H.B.; Tackaberry, L.E.; Payne, G.W.; Egger, K.N.; et al. Growth-Inhibitory and Immunomodulatory Activities of Wild Mushrooms from North-Central British Columbia (Canada). *Int. J. Med. Mushrooms* **2017**, *19*, 485–497. [[CrossRef](#)]
45. Lee, J.S.; Lee, K.R.; Lee, S.; Lee, H.J.; Yang, H.S.; Yeo, J.; Park, J.M.; Choi, B.H.; Hong, E.K. Polysaccharides Isolated from Liquid Culture Broth of *Inonotus obliquus* Inhibit the Invasion of Human Non-small Cell Lung Carcinoma Cells. *Biotechnol. Bioprocess Eng.* **2017**, *22*, 45–51. [[CrossRef](#)]
46. Fan, L.P.; Ding, S.D.; Ai, L.Z.; Deng, K.Q. Antitumor and immunomodulatory activity of water-soluble polysaccharide from *Inonotus obliquus*. *Carbohydr. Polym.* **2012**, *90*, 870–874. [[CrossRef](#)] [[PubMed](#)]
47. Zhang, L.X.; Fan, C.; Liu, S.C.; Zang, Z.F.; Jiao, L.L.; Zhang, L.P. Chemical composition and antitumor activity of polysaccharide from *Inonotus obliquus*. *J. Med. Plants Res.* **2011**, *5*, 1251–1260.
48. Lemieszek, M.K.; Langner, E.; Kaczor, J.; Kandefer-Szerszen, M.; Sanecka, B.; Mazurkiewicz, W.; Rzeski, W. Anticancer Effects of Fraction Isolated from Fruiting Bodies of Chaga Medicinal Mushroom, *Inonotus obliquus* (Pers.:Fr.) Pilat (Aphyllphoromyce-tidae): In Vitro Studies. *Int. J. Med. Mushrooms* **2011**, *13*, 131–143. [[CrossRef](#)] [[PubMed](#)]
49. Jie, Z. Study on *Inonotus obliquus* Polysaccharide Induced Apoptosis of Human Ovarian Cancer Cells. *Edible Fungi China* **2010**, *29*, 38–39.
50. Meuninck, J. *Foraging Mushrooms Oregon: Finding, Identifying, and Preparing Edible Wild Mushrooms*; Falcon Guides: Michigan, MI, USA, 2017; p. 111.
51. Tingjuan, Q.; Yubo, Z.; Yi, Z. Preliminary Study on the Physical and Chemical Properties and Biological Activity of Polysaccharide from *Inonotus obliquus*. *Smart Health* **2018**, *4*, 50–53.
52. Li, Z.G.; Mei, J.J.; Jiang, L.P.; Geng, C.Y.; Li, Q.J.; Yao, X.F.; Cao, J. Chaga Medicinal Mushroom *Inonotus obliquus* (Agaricomycetes) Polysaccharides Suppress Tacrine-Induced Apoptosis by Reactive Oxygen Species-Scavenging and Mitochondrial Pathway in HepG2 Cells. *Int. J. Med. Mushrooms* **2019**, *21*, 583–593. [[CrossRef](#)]

53. Han, Y.Q.; Nan, S.J.; Fan, J.; Chen, Q.H.; Zhang, Y.Z. Inonotus obliquus polysaccharides protect against Alzheimer's disease by regulating Nrf2 signaling and exerting antioxidative and antiapoptotic effects. *Int. J. Biol. Macromol.* **2019**, *131*, 769–778. [[CrossRef](#)]
54. Wang, C.; Santhanam, R.K.; Gao, X.; Chen, Z.; Chen, Y.; Wang, C.; Xu, L.; Chen, H. Preparation, characterization of polysaccharides fractions from Inonotus obliquus and their effects on alpha-amylase, alpha-glucosidase activity and H₂O₂ induced oxidative damage in hepatic L02 cells. *J. Funct. Foods* **2018**, *48*, 179–189. [[CrossRef](#)]
55. Wang, C.; Gao, X.; Santhanam, R.K.; Chen, Z.; Chen, Y.; Xu, L.; Wang, C.; Ferri, N.; Chen, H. Effects of polysaccharides from Inonotus obliquus and its chromium (III) complex on advanced glycation end-products formation, alpha-amylase, alpha-glucosidase activity and H₂O₂-induced oxidative damage in hepatic L02 cells. *Food Chem. Toxicol.* **2018**, *116*, 335–345. [[CrossRef](#)]
56. Jingbo, W. Optimization of Extraction Process of Inonotus obliquus Polysaccharides and Evaluation of Antioxidant Activity. *Food Nutr. China* **2017**, *23*, 46–49.
57. Hu, Y.; Shi, S.Y.; Lu, L.; Teng, C.Y.; Yu, S.M.; Wang, X.; Yu, M.; Liang, J.S.; Qu, J.J. Effects of Selenizing Modification on Characteristics and Antioxidant Activities of Inonotus obliquus Polysaccharide. *Macromol. Res.* **2017**, *25*, 222–230. [[CrossRef](#)]
58. Zheng, W.F.; Zhang, M.M.; Zhao, Y.X.; Miao, K.J.; Pan, S.Y.; Cao, F.; Dai, Y.C. Analysis of Antioxidant Metabolites by Solvent Extraction from Sclerotia of Inonotus obliquus (Chaga). *Phytochem. Anal.* **2011**, *22*, 95–102. [[CrossRef](#)]
59. Xu, X.Q.; Wu, Y.D.; Chen, H. Comparative antioxidative characteristics of polysaccharide-enriched extracts from natural sclerotia and cultured mycelia in submerged fermentation of Inonotus obliquus. *Food Chem.* **2011**, *127*, 74–79. [[CrossRef](#)]
60. Chen, H.; Yan, M.C.; Zhu, J.W.; Xu, X.Q. Enhancement of exo-polysaccharide production and antioxidant activity in submerged cultures of Inonotus obliquus by lignocellulose decomposition. *J. Ind. Microbiol. Biotechnol.* **2011**, *38*, 291–298. [[CrossRef](#)] [[PubMed](#)]
61. Xu, X.; Pang, C.; Yang, C.J.; Zheng, Y.T.; Xu, H.Y.; Lu, Z.M.; Xu, Z.H. Antihyperglycemic and Antilipidperoxidative Effects of Polysaccharides Extracted from Medicinal Mushroom Chaga, Inonotus obliquus (Pers.: Fr.) Pilat (Aphyllphoromycetidae) on Alloxan-Diabetes Mice. *Int. J. Med. Mushrooms* **2010**, *12*, 235–244. [[CrossRef](#)]
62. Lou, H.; Li, H.; Wei, T.; Chen, Q. Stimulatory Effects of Oleci Acid and Fungal Elicitor on Betulinic Acid Production by Submerged Cultivation of Medicinal Mushroom Inonotus obliquus. *J. Fungi (Basel Switzerland)* **2021**, *7*, 266. [[CrossRef](#)] [[PubMed](#)]
63. Zhang, Y.; Liu, R.; Liu, C.; Li, S.; Hou, W. Development of ultrasound-assisted centrifugal extraction combined with two countercurrent chromatography systems for the simultaneous extraction and isolation of phytochemicals. *J. Sep. Sci.* **2021**. [[CrossRef](#)]
64. Zhang, Z.; Liang, X.; Tong, L.; Lv, Y.; Yi, H.; Gong, P.; Tian, X.; Cui, Q.; Liu, T.; Zhang, L. Effect of Inonotus obliquus (Fr.) Pilat extract on the regulation of glycolipid metabolism via PI3K/Akt and AMPK/ACC pathways in mice. *J. Ethnopharmacol.* **2021**, *273*, 113963. [[CrossRef](#)] [[PubMed](#)]
65. Gao, W.; De-Shui, Y.U.; Liu, J.N.; Dai, X.D.; Han, Z.H. Extraction of Polysaccharide from Inonotus obliquus Fruit Bodies. *Biotechnology* **2012**. [[CrossRef](#)]
66. Liu, Z.D.; Yu, D.S.; Li, L.; Liu, X.X.; Zhang, H.A.; Sun, W.B.; Lin, C.C.; Chen, J.F.; Chen, Z.; Wang, W.H.; et al. Three-Phase Partitioning for the Extraction and Purification of Polysaccharides from the Immunomodulatory Medicinal Mushroom Inonotus obliquus. *Molecules* **2019**, *24*, 403. [[CrossRef](#)]
67. Joo, J.I.; Kim, D.H.; Yun, J.W. Extract of Chaga Mushroom (Inonotus obliquus) stimulates 3t3-l1 adipocyte differentiation. *Phytother. Res.* **2010**, *24*, 1592–1599. [[CrossRef](#)] [[PubMed](#)]
68. Kim, Y.O.; Park, H.W.; Kim, J.H.; Lee, J.Y.; Moon, S.H.; Shin, C.S. Anti-cancer effect and structural characterization of endo-polysaccharide from cultivated mycelia of Inonotus obliquus. *Life Sci.* **2006**, *79*, 72–80. [[CrossRef](#)] [[PubMed](#)]
69. Fu, L.L.; Chen, H.X.; Dong, P.; Zhang, X.; Zhang, M. Effects of Ultrasonic Treatment on the Physicochemical Properties and DPPH Radical Scavenging Activity of Polysaccharides from Mushroom Inonotus obliquus. *J. Food Sci.* **2010**, *75*, C322–C327. [[CrossRef](#)]
70. Semedo, M.C.; Karmali, A.; Fonseca, L. A high throughput colorimetric assay of beta-1,3-D-glucans by Congo red dye. *J. Microbiol. Meth.* **2015**, *109*, 140–148. [[CrossRef](#)] [[PubMed](#)]
71. Wang, J.; Wang, C.; Li, W.W.; Pan, Y.X.; Yuan, G.Q.; Chen, H.X. Ball milling improves extractability and antioxidant properties of the active constituents of mushroom Inonotus obliquus powders. *Int. J. Food Sci. Tech.* **2016**, *51*, 2193–2200. [[CrossRef](#)]
72. Patist, A.; Bates, D. Ultrasonic innovations in the food industry: From the laboratory to commercial production. *Innov. Food Sci. Emerg.* **2008**, *9*, 147–154. [[CrossRef](#)]
73. Shichun, Z.; Zhaocheng, Y.; Deyi, Z.; Kangjian, Z.; Jinming, G. Optimization of Extraction Technology for Polysaccharides in Inonotus Obliquus. *Chin. J. Mod. Appl. Pharm.* **2014**, *31*, 167–172.
74. Xintong, J.; Siyue, Z.; Jie, Z. Research on the optimization of exaction parameter for polysaccharide of Inonotus obliquus and its antioxidant activity. *J. Nat. Sci. Heilongjiang Univ.* **2017**, *34*, 584–594.
75. Yaoling, H.; Tengfei, X.; Zhongxiang, J. Studies on the Purification Methods of Crude polysaccharides of Inonotus Obliquus. *J. Henan Univ. (Med. Sci.)* **2012**, *31*, 229–232.
76. Qing, L. Study on Extraction, Purification and Anti-Tumor Activity of Polysaccharide from Inonotus Obliquus. Ph.D. Thesis, Qingdao University of Science and Technology, Qingdao, China, 2014.
77. Yang, X.; Wei, S.; Lu, X.; Qiao, X.; Simal-Gandara, J.; Capanoglu, E.; Wozniak, L.; Zou, L.; Cao, H.; Xiao, J.; et al. A neutral polysaccharide with a triple helix structure from ginger: Characterization and immunomodulatory activity. *Food Chem.* **2021**, *350*. [[CrossRef](#)]

78. Huang, Q.; He, W.; Khudoyberdiev, I.; Ye, C.-L. Characterization of polysaccharides from *Tetrastigma hemsleyanum* Diels et Gilg Roots and their effects on antioxidant activity and H₂O₂-induced oxidative damage in RAW 264.7 cells. *BMC Chem.* **2021**, *15*. [[CrossRef](#)] [[PubMed](#)]
79. Yang, L.Q.; Zhang, L.M. Chemical structural and chain conformational characterization of some bioactive polysaccharides isolated from natural sources. *Carbohydr. Polym.* **2009**, *76*, 349–361. [[CrossRef](#)]
80. Maity, P.; Sen, I.K.; Chakraborty, I.; Mondal, S.; Bar, H.; Bhanja, S.K.; Mandal, S.; Maity, G.N. Biologically active polysaccharide from edible mushrooms: A review. *Int. J. Biol. Macromol.* **2021**, *172*, 408–417. [[CrossRef](#)] [[PubMed](#)]
81. Wang, Y.; Zhang, H. Advances in the extraction, purification, structural-property relationships and bioactive molecular mechanism of *Flammulina velutipes* polysaccharides: A review. *Int. J. Biol. Macromol.* **2021**, *167*, 528–538. [[CrossRef](#)] [[PubMed](#)]
82. Guo, X.; Kang, J.; Xu, Z.; Guo, Q.; Zhang, L.; Ning, H.; Cui, S.W. Triple-helix polysaccharides: Formation mechanisms and analytical methods. *Carbohydr. Polym.* **2021**, *262*, 117962. [[CrossRef](#)] [[PubMed](#)]
83. Zhang, C.J.; Guo, J.Y.; Cheng, H.; Li, L.; Liu, Y.; Shi, Y.; Xu, J.; Yu, H.T. Spatial structure and anti-fatigue of polysaccharide from *Inonotus obliquus*. *Int. J. Biol. Macromol.* **2020**, *151*, 855–860. [[CrossRef](#)]
84. Chen, Q.C.; Mao, R.; Zhao, J.J.; Bi, X.Y.; Li, Z.Y.; Huang, Z.; Zhang, Y.F.; Zhou, J.G.; Zhao, H.; Cai, J.Q. From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing? *Cancer Med.* **2020**. [[CrossRef](#)]
85. Chung, M.J.; Chung, C.K.; Jeong, Y.; Ham, S.S. Anticancer activity of subfractions containing pure compounds of Chaga mushroom (*Inonotus obliquus*) extract in human cancer cells and in Balbc/c mice bearing Sarcoma-180 cells. *Nutr. Res. Pract.* **2010**, *4*, 177–182. [[CrossRef](#)]
86. Heavey, S.; O'Byrne, K.J.; Gately, K. Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. *Cancer Treat. Rev.* **2014**, *40*, 445–456. [[CrossRef](#)]
87. Kopru, B.; Ebiloglu, T.; Kaya, E.; Alagoz, E.; Zor, M.; Emer, M.O.; Gurdal, M.; Bedir, S.; Arslan, N. What is the Prostate Specific Antigen Cut-off Value to Detect Metastases in Ga-68 Prostate Specific Membrane Antigen Ligand Positron Emission Tomography/Computer Tomography Imaging for Intermediate and High-risk Prostate Cancer? *Uroonkoloji Bulteni Bull. Urooncology* **2020**, *19*, 151–156. [[CrossRef](#)]
88. Mensah, K.B.; Mensah, A.B.B.; Bangalee, V.; Oosthuizen, F. Awareness is the first step: What Ghanaian community pharmacists know about cancer. *J. Oncol. Pharm. Pract.* **2020**, 1078155220955211. [[CrossRef](#)]
89. Sciacovelli, M.; Schmidt, C.; Maher, E.R.; Frezza, C. Metabolic Drivers in Hereditary Cancer Syndromes. *Annu Rev. Cancer Biol.* **2020**, *4*, 77–97. [[CrossRef](#)]
90. Subotic, S.; Wyler, S.; Bachmann, A. Surgical Treatment of Localised Renal Cancer. *Eur. Urol. Suppl.* **2012**, *11*, 60–65. [[CrossRef](#)]
91. Wang, H.D.; Naghavi, M.; Allen, C.; Barber, R.M.; Bhutta, Z.A.; Carter, A.; Casey, D.C.; Charlson, F.J.; Chen, A.Z.; Coates, M.M.; et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. *Lancet* **2016**, *388*, 1459–1544. [[CrossRef](#)]
92. Joseph, M.M.; Aravind, S.R.; George, S.K.; Pillai, K.R.; Mini, S.; Sreelekha, T.T. Antitumor activity of galactoxyloglucan-gold nanoparticles against murine ascites and solid carcinoma. *Colloid Surf. B* **2014**, *116*, 219–227. [[CrossRef](#)] [[PubMed](#)]
93. Sun, Q.; You, Q.; Wang, J.; Liu, L.; Wang, Y.; Song, Y.; Cheng, Y.; Wang, S.; Tan, F.; Li, N. Theranostic Nanoplatform: Triple-Modal Imaging-Guided Synergistic Cancer Therapy Based on Liposome-Conjugated Mesoporous Silica Nanoparticles. *ACS Appl. Mater. Interfaces* **2018**, *10*, 1963–1975. [[CrossRef](#)] [[PubMed](#)]
94. Song, F.Q.; Liu, Y.; Kong, X.S.; Chang, W.; Song, G. Progress on Understanding the Anticancer Mechanisms of Medicinal Mushroom: *Inonotus Obliquus*. *Asian Pac. J. Cancer Prev.* **2013**, *14*, 1571–1578. [[CrossRef](#)] [[PubMed](#)]
95. Huili, Z.; Song, Y.; Yu, L. Extraction of *Inonotus obliquus* polysaccharide and the effect of anti-proliferation on SMMC7721 cells of lung cancer. *Edible Fungi China* **2006**, *25*, 31–33.
96. Lee, K.R.; Lee, J.S.; Lee, S.; Son, Y.K.; Kim, G.R.; Sim, Y.C.; Song, J.E.; Ha, S.J.; Hong, E.K. Polysaccharide isolated from the liquid culture broth of *Inonotus obliquus* suppresses invasion of B16-F10 melanoma cells via AKT/NF-kappa B signaling pathway. *Mol. Med. Rep.* **2016**, *14*, 4429–4435. [[CrossRef](#)]
97. Lee, K.R.; Lee, J.S.; Song, J.E.; Ha, S.J.; Hong, E.K. *Inonotus obliquus*-derived polysaccharide inhibits the migration and invasion of human non-small cell lung carcinoma cells via suppression of MMP-2 and MMP-9. *Int. J. Oncol.* **2014**, *45*, 2533–2540. [[CrossRef](#)]
98. Yi-yong, C.; Xiao-hong, G.; Jian, T. Study on Anti-Tumor Activities of Polysaccharides from *Inonotus obliquus*. *J. Food Sci. Biotechnol.* **2011**, *30*, 65–69.
99. Yan, L. Research on Deep Cultivation of *Inonotus Obliquus* and Extraction Technology and Anti-Tumor Activity of Its Polysaccharide. Master's Thesis, Fujian Agriculture and Forestry University, Fuzhou, China, 2009.
100. Jiang, S.P.; Shi, F.L.; Lin, H.; Ying, Y.; Luo, L.Y.; Huang, D.Q.; Luo, Z.J. *Inonotus obliquus* polysaccharides induces apoptosis of lung cancer cells and alters energy metabolism via the LKB1/AMPK axis. *Int. J. Biol. Macromol.* **2020**, *151*, 1277–1286. [[CrossRef](#)] [[PubMed](#)]
101. Su, B.H.; Yan, X.Z.; Li, Y.Z.; Zhang, J.S.; Xia, X.Y. Effects of *Inonotus obliquus* Polysaccharides on Proliferation, Invasion, Migration, and Apoptosis of Osteosarcoma Cells. *Anal. Cell Pathol.* **2020**, 2020. [[CrossRef](#)] [[PubMed](#)]
102. Min, Y. The inhibitory Effect of Water Extract of *Inonotus Obliquus* on Human Hepatocarcinoma Cell Line HepG2. Master's Thesis, Tianjin University of Science and Technology, Tianjin, China, 2019.

103. Gang, L. Preliminary Study on the Physical and Chemical Properties and Biological Activity of Polysaccharide from *Inonotus obliquus*. Master's Thesis, Northeast Normal University, Changchun, China, 2008.
104. Xie, J.H.; Jin, M.L.; Morris, G.A.; Zha, X.Q.; Chen, H.Q.; Yi, Y.; Li, J.E.; Wang, Z.J.; Gao, J.; Nie, S.P.; et al. Advances on Bioactive Polysaccharides from Medicinal Plants. *Crit. Rev. Food Sci.* **2016**, *56*, S60–S84. [[CrossRef](#)]
105. He, P.; Zhang, Y.; Li, N. The phytochemistry and pharmacology of medicinal fungi of the genus *Phellinus*: A review. *Food Funct.* **2021**, *12*, 1856–1881. [[CrossRef](#)] [[PubMed](#)]
106. Alejandrina Virgen-Carrillo, C.; Martinez Moreno, A.G.; Valdes Miramontes, E.H. Potential Hypoglycemic Effect of Pomegranate Juice and Its Mechanism of Action: A Systematic Review. *J. Med. Food* **2020**, *23*, 1–11. [[CrossRef](#)]
107. Guo, M.; Shao, S.; Wang, D.; Zhao, D.; Wang, M. Recent progress in polysaccharides from *Panax ginseng* C. A. Meyer. *Food Funct.* **2021**, *12*, 494–518. [[CrossRef](#)]
108. Shen, J.; Hu, M.; Tan, W.; Ding, J.; Jiang, B.; Xu, L.; Hamulati, H.; He, C.; Sun, Y.; Xiao, P. Traditional uses, phytochemistry, pharmacology, and toxicology of *Coreopsis tinctoria* Nutt.: A review. *J. Ethnopharmacol.* **2021**, *269*. [[CrossRef](#)] [[PubMed](#)]
109. Luan, F.; Ji, Y.; Peng, L.; Liu, Q.; Cao, H.; Yang, Y.; He, X.; Zeng, N. Extraction, purification, structural characteristics and biological properties of the polysaccharides from *Codonopsis pilosula*: A review. *Carbohydr. Polym.* **2021**, *261*. [[CrossRef](#)] [[PubMed](#)]
110. Bao, Y.-H.; Sun, K.-F.; Guo, Y. Effect of molecular weight on hypolipidemic and hypoglycemic activities of fermented *Auricularia auricula* supernatant. *Food Sci. Technol.* **2020**, *40*, 106–112. [[CrossRef](#)]
111. Chen, H.X.; Lu, X.M.; Qu, Z.S.; Wang, Z.S.; Zhang, L.P. Glycosidase Inhibitory Activity and Antioxidant Properties of a Polysaccharide from the Mushroom *Inonotus Obliquus*. *J. Food Biochem.* **2010**, *34*, 178–191. [[CrossRef](#)]
112. Liu, P.; Xue, J.; Tong, S.S.; Dong, W.X.; Wu, P.P. Structure Characterization and Hypoglycaemic Activities of Two Polysaccharides from *Inonotus obliquus*. *Molecules* **2018**, *23*, 1948. [[CrossRef](#)] [[PubMed](#)]
113. Cui, Y.; Kim, D.S.; Park, K.C. Antioxidant effect of *Inonotus obliquus*. *J. Ethnopharmacol.* **2005**, *96*, 79–85. [[CrossRef](#)]
114. Azeem, U.; Shri, R.; Dhingra, G.S. In Vitro Antioxidant Efficacy of Some Selected Medicinal Mushrooms from India. *Int. J. Med. Mushrooms* **2020**, *22*, 641–649. [[CrossRef](#)]
115. Xu, X.Q.; Zhao, W.; Shen, M.W. Antioxidant activity of liquid cultured *Inonotus obliquus* polyphenols using tween-20 as a stimulatory agent: Correlation of the activity and the phenolic profiles. *J. Taiwan Inst. Chem. E* **2016**, *69*, 41–47. [[CrossRef](#)]
116. Ma, L.S.; Chen, H.X.; Zhang, Y.; Zhang, N.; Fu, L.L. Chemical modification and antioxidant activities of polysaccharide from mushroom *Inonotus obliquus*. *Carbohydr. Polym.* **2012**, *89*, 371–378. [[CrossRef](#)]
117. Hu, Y.; Sheng, Y.; Yu, M.; Li, K.K.; Ren, G.M.; Xu, X.H.; Qu, J.J. Antioxidant activity of *Inonotus obliquus* polysaccharide and its amelioration for chronic pancreatitis in mice. *Int. J. Biol. Macromol.* **2016**, *87*, 348–356. [[CrossRef](#)] [[PubMed](#)]
118. Zhang, N.; Chen, H.X.; Ma, L.S.; Zhang, Y. Physical modifications of polysaccharide from *Inonotus obliquus* and the antioxidant properties. *Int. J. Biol. Macromol.* **2013**, *54*, 209–215. [[CrossRef](#)]
119. Ma, L.S.; Chen, H.X.; Zhu, W.C.; Wang, Z.S. Effect of different drying methods on physicochemical properties and antioxidant activities of polysaccharides extracted from mushroom *Inonotus obliquus*. *Food Res. Int.* **2013**, *50*, 633–640. [[CrossRef](#)]
120. Chen, H.; Xu, X.Q.; Zhu, Y. Optimization of Hydroxyl Radical Scavenging Activity of Exopolysaccharides from *Inonotus obliquus* in Submerged Fermentation Using Response Surface Methodology. *J. Microbiol. Biotechn.* **2010**, *20*, 835–843.
121. Xu, X.Q.; Wu, P.; Wang, T.Z.; Yan, L.L.; Lin, M.M.; Chen, C. Synergistic effects of surfactant-assisted biodegradation of wheat straw and production of polysaccharides by *Inonotus obliquus* under submerged fermentation. *Bioresour. Technol.* **2019**, *278*, 43–50. [[CrossRef](#)] [[PubMed](#)]
122. Du, X.J.; Mu, H.M.; Zhou, S.; Zhang, Y.; Zhu, X.L. Chemical analysis and antioxidant activity of polysaccharides extracted from *Inonotus obliquus* sclerotia. *Int. J. Biol. Macromol.* **2013**, *62*, 691–696. [[CrossRef](#)] [[PubMed](#)]
123. Zhou, L.W.; Dai, Y.C. Progress report on the study of wood-decaying fungi in China. *Chin. Sci. Bull.* **2012**, *57*, 4328–4335. [[CrossRef](#)]
124. Xiang, Y.L.; Xu, X.Q.; Li, J. Chemical properties and antioxidant activity of exopolysaccharides fractions from mycelial culture of *Inonotus obliquus* in a ground corn stover medium. *Food Chem.* **2012**, *134*, 1899–1905. [[CrossRef](#)]
125. Mu, H.B.; Zhang, A.M.; Zhang, W.X.; Cui, G.T.; Wang, S.C.; Duan, J.Y. Antioxidative Properties of Crude Polysaccharides from *Inonotus obliquus*. *Int. J. Mol. Sci.* **2012**, *13*, 9194–9206. [[CrossRef](#)]
126. Huang, S.Q.; Ding, S.D.; Fan, L.P. Antioxidant activities of five polysaccharides from *Inonotus obliquus*. *Int. J. Biol. Macromol.* **2012**, *50*, 1183–1187. [[CrossRef](#)]
127. Sim, Y.C.; Lee, J.S.; Lee, S.; Son, Y.K.; Park, J.E.; Song, J.E.; Ha, S.J.; Hong, E.K. Effects of polysaccharides isolated from *Inonotus obliquus* against hydrogen peroxide-induced oxidative damage in RINm5F pancreatic beta-cells. *Mol. Med. Rep.* **2016**, *14*, 4263–4270. [[CrossRef](#)]
128. Xu, X.Q.; Hu, Y.; Quan, L.L. Production of bioactive polysaccharides by *Inonotus obliquus* under submerged fermentation supplemented with lignocellulosic biomass and their antioxidant activity. *Bioprocess Biosyst. Eng.* **2014**, *37*, 2483–2492. [[CrossRef](#)]
129. Zhong, Y.; Zhong, X.H.; Yang, S.Y.; Zheng, Z.H. Effect of *Inonotus Obliquus* Polysaccharides on physical fatigue in mice. *J. Tradit. Chin. Med.* **2015**, *35*, 468–472.
130. Koonin, E.V.; Senkevich, T.G.; Dolja, V.V. The ancient Virus World and evolution of cells. *Biol. Direct* **2006**, *1*, 29. [[CrossRef](#)]
131. University, J.H. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available online: <https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6> (accessed on 18 March 2021).

132. Van, Q.; Nayak, B.N.; Reimer, M.; Jones, P.J.H.; Fulcher, R.G.; Rempel, C.B. Anti-inflammatory effect of *Inonotus obliquus*, *Polygala senega* L., and *Viburnum trilobum* in a cell screening assay. *J. Ethnopharmacol.* **2009**, *125*, 487–493. [[CrossRef](#)] [[PubMed](#)]
133. Shahzad, F.; Anderson, D.; Najafzadeh, M. The Antiviral, Anti-Inflammatory Effects of Natural Medicinal Herbs and Mushrooms and SARS-CoV-2 Infection. *Nutrients* **2020**, *12*, 2573. [[CrossRef](#)]
134. Tian, J.; Hu, X.L.; Liu, D.F.; Wu, H.X.; Qu, L.D. Identification of *Inonotus obliquus* polysaccharide with broad-spectrum antiviral activity against multi-feline viruses. *Int. J. Biol. Macromol.* **2017**, *95*, 160–167. [[CrossRef](#)] [[PubMed](#)]
135. Pan, H.H.; Yu, X.T.; Li, T.; Wu, H.L.; Jiao, C.W.; Cai, M.H.; Li, X.M.; Xie, Y.Z.; Wang, Y.; Peng, T. Aqueous Extract from a Chaga Medicinal Mushroom, *Inonotus obliquus* (Higher Basidiomycetes), Prevents Herpes Simplex Virus Entry Through Inhibition of Viral-Induced Membrane Fusion. *Int. J. Med. Mushrooms* **2013**, *15*, 29–38. [[CrossRef](#)] [[PubMed](#)]
136. Ichimura, T.; Watanabe, O.; Maruyama, S. Inhibition of HIV-1 protease by water-soluble lignin-like substance from an edible mushroom, *Fuscoporia obliqua*. *Biosci. Biotechnol. Biochem.* **1998**, *62*, 575–577. [[CrossRef](#)]
137. Won, D.P.; Lee, J.S.; Kwon, D.S.; Lee, K.E.; Shin, W.C.; Hong, E.K. Immunostimulating activity by polysaccharides isolated from fruiting body of *Inonotus obliquus*. *Mol. Cells* **2011**, *31*, 165–173. [[CrossRef](#)] [[PubMed](#)]
138. Jinjuan, Z. The effect of *Inonotus Obliquus* Polysaccharides on Cell Inflammation Model and Its Possible Mechanism Based on the Signaling Pathway of NLRP3 Inflammasome. Master's Thesis, Yanbian University, Yanbian, China, 2019.
139. Xiao, Y.; Zheng, J.J.; Chen, Y.F.; Qu, C.; Bo, L.; Li, J.W.; Jin, D. *Inonotus obliquus* polysaccharides ameliorated inflammation of LPS-stimulated RAW264.7 macrophages involving inhibited NLRP3 inflammasome. *Eur J. Immunol.* **2019**, *49*, 230.
140. Harikrishnan, R.; Balasundaram, C.; Heo, M.S. Effect of *Inonotus obliquus* enriched diet on hematology, immune response, and disease protection in kelp grouper, *Epinephelus bruneus* against *Vibrio harveyi*. *Aquaculture* **2012**, *344*, 48–53. [[CrossRef](#)]
141. Hu, Y.; Teng, C.Y.; Yu, S.M.; Wang, X.; Liang, J.S.; Bai, X.; Dong, L.Y.; Song, T.; Yu, M.; Qu, J.J. *Inonotus obliquus* polysaccharide regulates gut microbiota of chronic pancreatitis in mice. *AMB Express* **2017**, *7*, 1–11. [[CrossRef](#)] [[PubMed](#)]
142. Chen, Y.F.; Zheng, J.J.; Qu, C.; Xiao, Y.; Li, F.F.; Jin, Q.X.; Li, H.H.; Meng, F.P.; Jin, G.H.; Jin, D. *Inonotus obliquus* polysaccharide ameliorates dextran sulphate sodium induced colitis involving modulation of Th1/Th2 and Th17/Treg balance. *Artif. Cells Nanomed. Biotechnol.* **2019**, *47*, 757–766. [[CrossRef](#)] [[PubMed](#)]
143. Xu, L.; Sang, R.; Yu, Y.F.; Li, J.X.; Ge, B.J.; Zhang, X.M. The polysaccharide from *Inonotus obliquus* protects mice from *Toxoplasma gondii*-induced liver injury. *Int. J. Biol. Macromol.* **2019**, *125*, 1–8. [[CrossRef](#)] [[PubMed](#)]
144. Chen, S.; Wu, Q.; Guan, X.; Xie, Y. *Inonotus Obliquus* Polysaccharide Extract Useful for Preparing Drug for Treating Atopic Dermatitis, Food Allergy, Allergic Rhinitis or Asthma, Comprises Mannose, Glucose, Galactose and Xylose. CN112409503-A, 26 February 2021.
145. Gao, X.D.; Santhanam, R.K.; Xue, Z.H.; Jia, Y.A.; Wang, Y.J.; Lu, Y.P.; Phisalaphong, M.; Chen, H.X. Antioxidant, alpha-amylase and alpha-glucosidase activity of various solvent fractions of *I. obliquus* and the preventive role of active fraction against H₂O₂ induced damage in hepatic L02 cells as fungisome. *J. Food Sci.* **2020**, *85*, 1060–1069. [[CrossRef](#)] [[PubMed](#)]
146. Wang, C.; Chen, Z.Q.; Pan, Y.X.; Gao, X.D.; Chen, H.X. Anti-diabetic effects of *Inonotus obliquus* polysaccharides-chromium (III) complex in type 2 diabetic mice and its sub-acute toxicity evaluation in normal mice. *Food Chem. Toxicol.* **2017**, *108*, 498–509. [[CrossRef](#)] [[PubMed](#)]
147. Szychowski, K.A.; Skóra, B.; Pomianek, T.; Gmiński, J. *Inonotus obliquus*—from folk medicine to clinical use. *J. Tradit. Complementary Med.* **2020**. [[CrossRef](#)]
148. Chen, H.J.; Liou, B.K.; Hsu, K.C.; Chen, C.S.; Chuang, P.T. Implementation of food safety management systems that meets ISO 22000:2018 and HACCP: A case study of capsule biotechnology products of chaga mushroom. *J. Food Sci.* **2021**, *86*, 40–54. [[CrossRef](#)]
149. Guo, S.; Li, G.; Li, Y.; Guo, X.; Nan, X. *Inonotus Obliquus* Hypoglycemic Beverage Comprises Extracts of *Inonotus Obliquus*, Kudzu Vine Root, Fructus Lycii and Ginseng. CN109673790A, 26 April 2019.
150. Liu, F.; Yang, F.; Zhao, H. Healthcare Food Used e.g., for Preventing and Treating Diabetes, Comprises *Inonotus Obliquus* Polysaccharide, *Ganoderma Lucidum* Peptide Polysaccharide, and *Tremella* Polysaccharide. CN104366193A, 25 February 2015.
151. Xu, L.; Lu, X.; Guo, L.; Ji, J. Functional Yogurt Used for Improving Immunity, Comprises Fresh Milk, *Inonotus Obliquus* Extracting Solution, *Ganoderma Lucidum* Spore Powder Polysaccharide, *Tremella* Concentrated Slurry, Xylitol and Fermentation Agent. CN108902307A, 30 November 2018.